Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.71 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.71 |
| ▸ | THRB | P10828 | 1/20 | 0.71 |
| ▸ | BACE1 | P56817 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | PTGFR | P43088 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | CRHBP | P24387 | 1/20 | 0.50 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4138365 | 0.90 | MAPT (0.62) | MAPTRXFP1THRBBACE1TP53 | |
| SCHEMBL4142299 | 0.88 | MAPT (0.55) | MAPTRXFP1THRBLMNA | |
| SCHEMBL4154944 | 0.85 | MAPT (0.50) | MAPTRXFP1THRBBACE1 | |
| SCHEMBL4138117 | 0.85 | PDE4A (0.58) | MAPTRXFP1THRBTP53 | |
| SCHEMBL6489253 | 0.84 | MAPT (0.83) | MAPTRXFP1THRBBACE1TP53 | |
| SCHEMBL4138267 | 0.83 | MAPT (0.62) | MAPTRXFP1THRBBACE1TP53 | |
| SCHEMBL4139018 | 0.82 | LMNA (0.48) | MAPTLMNA | |
| SCHEMBL4142530 | 0.82 | MAPK14 (0.52) | MAPTRXFP1THRB | |
| SCHEMBL4133197 | 0.82 | MAPT (0.57) | MAPTTP53LMNA | |
| SCHEMBL4145093 | 0.82 | LMNA (0.47) | MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009817-A1 | Substituted heteroaryls | INSTITUTES FOR PHARMACEUTICAL DISCOVERY, L.L.C. | 2005-01-13 | — | — | US | claimed |
| EP-1618094-B1 | SUBSTITUTED HETEROARYLS AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INST FOR PHARM DISCOVERY INC (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20050009817-A1 | Substituted heteroaryls | INSTITUTES FOR PHARMACEUTICAL DISCOVERY, L.L.C. | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009817-A1 | Substituted heteroaryls | PTPRS, PTPRO, PTPRR | MAPT 1878/4885RXFP1 4220/4885THRB 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.